🇺🇸 FDA
Pipeline program

Ivonescimab

UC-GIG-2404 - PRODIGE 110

Phase 2 small_molecule active

Quick answer

Ivonescimab for Biliary Tract Cancer is a Phase 2 program (small_molecule) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Summit Therapeutics
Indication
Biliary Tract Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials